



# Maternal Glycemic Dysregulation During Pregnancy and Neonatal Blood DNA Methylation: Meta-analyses of Epigenome-Wide Association Studies

*Diabetes Care* 2022;45:614–623 | <https://doi.org/10.2337/dc21-1701>

## OBJECTIVE

Maternal glycemic dysregulation during pregnancy increases the risk of adverse health outcomes in her offspring, a risk thought to be linearly related to maternal hyperglycemia. It is hypothesized that changes in offspring DNA methylation (DNAm) underline these associations.

## RESEARCH DESIGN AND METHODS

To address this hypothesis, we conducted fixed-effects meta-analyses of epigenome-wide association study (EWAS) results from eight birth cohorts investigating relationships between cord blood DNAm and fetal exposure to maternal glucose ( $N_{\text{maximum}} = 3,503$ ), insulin ( $N_{\text{maximum}} = 2,062$ ), and area under the curve of glucose ( $AUC_{\text{gluc}}$ ) following oral glucose tolerance tests ( $N_{\text{maximum}} = 1,505$ ). We performed lookup analyses for identified cytosine-guanine dinucleotides (CpGs) in independent observational cohorts to examine associations between DNAm and cardiometabolic traits as well as tissue-specific gene expression.

## RESULTS

Greater maternal  $AUC_{\text{gluc}}$  was associated with lower cord blood DNAm at neighboring CpGs cg26974062 ( $\beta$  [SE]  $-0.013$  [ $2.1 \times 10^{-3}$ ],  $P$  value corrected for false discovery rate [ $P_{\text{FDR}}] = 5.1 \times 10^{-3}$ ) and cg02988288 ( $\beta$  [SE]  $-0.013$  [ $2.3 \times 10^{-3}$ ],  $P_{\text{FDR}} = 0.031$ ) in *TXNIP*. These associations were attenuated in women with GDM. Lower blood DNAm at these two CpGs near *TXNIP* was associated with multiple metabolic traits later in life, including type 2 diabetes. *TXNIP* DNAm in liver biopsies was associated with hepatic expression of *TXNIP*. We observed little evidence of associations between either maternal glucose or insulin and cord blood DNAm.

## CONCLUSIONS

Maternal hyperglycemia, as reflected by  $AUC_{\text{gluc}}$ , was associated with lower cord blood DNAm at *TXNIP*. Associations between DNAm at these CpGs and metabolic traits in subsequent lookup analyses suggest that these may be candidate loci to investigate in future causal and mediation analyses.

Gestational diabetes mellitus (GDM) has major health consequences for both mother and child (1–3). Even among women without GDM, maternal hyperglycemia and

Elmar W. Tobi,<sup>1</sup>  
 Diana L. Juvinao-Quintero,<sup>2</sup>  
 Justiina Ronkainen,<sup>3</sup> Raffael Ott,<sup>4,5,6</sup>  
 Rossella Alfano,<sup>7</sup> Mickaël Canouil,<sup>8,9</sup>  
 Madelon L. Geurtsen,<sup>10,11</sup>  
 Amna Khamis,<sup>8,9,12</sup> Leanne K. Küpers,<sup>10,11</sup>  
 Ives Y. Lim,<sup>13,14</sup> Patrice Perron,<sup>15,16</sup>  
 Giancarlo Pesce,<sup>17,18</sup>  
 Johanna Tuhkanen,<sup>19</sup>  
 Anne P. Starling,<sup>20,21</sup> Toby Andrew,<sup>12</sup>  
 Elisabeth Binder,<sup>22,23</sup> Robert Caiazzo,<sup>24</sup>  
 Jerry K.Y. Chan,<sup>25,26</sup> Romy Gaillard,<sup>10,11</sup>  
 Peter D. Gluckman,<sup>14,27</sup>  
 Elina Keikkala,<sup>28,29</sup> Neerja Karnani,<sup>13,14,30</sup>  
 Sanna Mustaniemi,<sup>28,29</sup> Tim S. Nawrot,<sup>7</sup>  
 François Pattou,<sup>24</sup> Michelle Plusquin,<sup>7</sup>  
 Violeta Raverdy,<sup>24</sup> Kok Hian Tan,<sup>26,31</sup>  
 Evangelia Tzala,<sup>32</sup> Katri Raikkonen,<sup>19</sup>  
 Christiane Winkler,<sup>4,5,6</sup>  
 Anette-G. Ziegler,<sup>4,5,6</sup>  
 Isabella Annesi-Maesano,<sup>33</sup>  
 Luigi Bouchard,<sup>34,35</sup> Yap Seng Chong,<sup>14,36</sup>  
 Dana Dabelea,<sup>20,21,37</sup> Janine F. Felix,<sup>10,11</sup>  
 Barbara Heude,<sup>38</sup>  
 Vincent W.V. Jaddoe,<sup>10,11</sup> Jari Lahti,<sup>19</sup>  
 Brigitte Reimann,<sup>7</sup> Marja Väärasmäki,<sup>29</sup>  
 Amélie Bonnefond,<sup>8,9,12</sup>  
 Philippe Froguel,<sup>8,9,12</sup>  
 Sandra Hummel,<sup>4,5,6</sup>  
 Eero Kajantie,<sup>28,29,39,40</sup>  
 Marjo-Riita Jarvelin,<sup>3,32,41,42</sup>  
 Regine P.M. Steegers-Theunissen,<sup>1</sup>  
 Caitlin G. Howe,<sup>43</sup>  
 Marie-France Hivert,<sup>2,44</sup> and  
 Sylvain Sebert<sup>3</sup>

<sup>1</sup>Division of Obstetrics and Prenatal Medicine, Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, the Netherlands

<sup>2</sup>Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA

<sup>3</sup>Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland

<sup>4</sup>Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany

<sup>5</sup>Forschergruppe Diabetes, Technical University Munich, Klinikum rechts der Isar, Munich, Germany

<sup>6</sup>Forschergruppe Diabetes e.V., Helmholtz Zentrum München, Munich-Neuherberg, Germany

<sup>7</sup>Center for Environmental Sciences, University of Hasselt, Hasselt, Belgium

hyperinsulinemia have been associated with increased risk for pregnancy complications (1) and offspring cardiometabolic disease (3). The latter relationships are hypothesized to be mediated by alterations in epigenetic factors, including DNA methylation (DNAm), laid down during prenatal development (4). Single cohort studies have reported associations between GDM or maternal glycemic measures and offspring DNAm (5–8). The most comprehensive study to date has been a Pregnancy and Childhood Epigenetics (PACE) consortium meta-analysis of epigenome-wide association studies (EWAS) with assessment of the association between GDM diagnosis and cord blood DNAm (9). This study did not find evidence for robust associations between mother's GDM status and offspring DNAm at the single cytosine-guanine dinucleotide (CpG) level, suggesting that GDM may not influence changes in the fetal epigenome. However, this may also be partly

explained by methodological limitations such as the heterogeneous definitions of GDM, differences in GDM treatment across cohorts, or limited statistical power to identify changes across the DNA methylome ( $N = 317$  cases of GDM). In addition, GDM diagnosis is a clinical threshold dichotomizing glucose levels, yet linear associations have been reported between various measures of glucose metabolism and offspring outcomes (3). We therefore opted to evaluate continuous measures of maternal glycemic dysregulation in relation to offspring DNAm.

In the current study, we conducted fixed-effects meta-analyses of EWAS investigating associations between continuous maternal glucose, insulin, and area under the curve of glucose ( $AUC_{gluc}$ ) measures from an oral glucose tolerance tests (OGTT) conducted during pregnancy and cord blood DNAm. We used  $AUC_{gluc}$  as one of our exposures of interest, as glucose measures at different OGTT time points show similar linear

associations with health outcomes (1) and capture both fasting and nonfasting maternal glycemic regulation (10). The findings from the meta-analyses were subsequently looked up in complementary observational studies for assessment of whether the variation of DNAm at identified CpGs also potentially associated with cardiometabolic traits in children (11) and adults (12). Additionally, we performed lookup analyses investigating relationships between DNAm at these CpGs and gene expression in two relevant human tissues (13).

## RESEARCH DESIGN AND METHODS

### Participating Cohorts

Seven cohorts with cord blood DNAm and fasting glycemic data in midpregnancy participated in the meta-analyses (Table 1 and Supplementary Material). These cohorts were from Southeast Asia (Singapore: Growing Up in Singapore Towards healthy Outcomes [GUSTO] [14]), North America (Canada: Genetics

<sup>8</sup>INSERM U1283, CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France

<sup>9</sup>University of Lille, Lille University Hospital, Lille, France

<sup>10</sup>The Generation R Study Group, Erasmus MC, Rotterdam, the Netherlands

<sup>11</sup>Department of Pediatrics, Erasmus MC, Rotterdam, the Netherlands

<sup>12</sup>Department of Metabolism, Digestion and Reproduction, Imperial College London, London, U.K.

<sup>13</sup>Bioinformatics Institute, A\*STAR, Singapore

<sup>14</sup>Singapore Institute for Clinical Sciences, A\*STAR, Singapore

<sup>15</sup>Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada

<sup>16</sup>Research Center, Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada

<sup>17</sup>Paris-Saclay University, Paris-South University, UVSQ, Center for Research in Epidemiology and Population Health (CESP), INSERM, Villejuif, France

<sup>18</sup>Sorbonne Université and INSERM, Team EPAR, Institut Pierre Louis D'Épidémiologie et de Santé Publique, Paris, France

<sup>19</sup>Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland

<sup>20</sup>Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO

<sup>21</sup>Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, Aurora, CO

<sup>22</sup>Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany

<sup>23</sup>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA

<sup>24</sup>University of Lille, CHU Lille, Inserm, Institut Pasteur Lille, U1190 Translational Research for Diabetes, Lille, France

<sup>25</sup>Department of Reproductive Medicine, KK Women's and Children's Hospital, Singapore

<sup>26</sup>Academic Clinical Program in Obstetrics and Gynaecology, Duke-NUS Medical School, Singapore

<sup>27</sup>Liggins Institute, University of Auckland, Auckland, New Zealand

<sup>28</sup>Population Health Unit, Finnish Institute for Health and Welfare, Oulu, Finland

<sup>29</sup>PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

<sup>30</sup>Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>31</sup>Department of Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore

<sup>32</sup>MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, U.K.

<sup>33</sup>Montpellier University, INSERM, Institut Desbrest d'Épidémiologie et de Santé Publique (IDESP), Montpellier, France

<sup>34</sup>Department of Biochemistry and Functional Genomics, Université de Sherbrooke, Sherbrooke, Canada

<sup>35</sup>Department of Laboratory Medicine, CIUSSS du Saguenay-Lac-St-Jean, Hôpital Universitaire de Chicoutimi, Canada

<sup>36</sup>Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National

University of Singapore, National University Health System, Singapore

<sup>37</sup>Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO

<sup>38</sup>Université de Paris, Inserm, INRAE, Centre for Research in Epidemiology and Statistics (CRESS), Paris, France

<sup>39</sup>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

<sup>40</sup>Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

<sup>41</sup>Unit of Primary Health Care, Oulu University Hospital, Oulu, Finland

<sup>42</sup>Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, U.K.

<sup>43</sup>Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH

<sup>44</sup>Diabetes Unit, Massachusetts General Hospital, Boston, MA

Corresponding author: Elmar W. Tobi, [e.tobi@erasmusmc.nl](mailto:e.tobi@erasmusmc.nl)

Received 13 August 2021 and accepted 10 December 2021

This article contains supplementary material online at <https://doi.org/10.2337/figshare.17209262>.

C.G.H., M.-F.H., and S.S. made equal contributions.

© 2022 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/journals/pages/license>.

Table 1—Cohort characteristics

Cohort	Ancestry	Array	Sample size n (% female)	Mat. age, years	Mat. prepregnancy BMI, kg/m <sup>2</sup>	Multiparous (%)	GA at glycemic measure, days	GA at birth, days	FG, mmol/L	FI, pmol/L	AUC <sub>gluc</sub> mmol/L*min
EDEN	French European	450k	53 (41.5)	31.1 (5.7)	24.4 (5.7)	72	172 (19)	264 (11)	4.38 (0.45)	—	882 (111)
FinnGeDi-control	Finnish European	EPIC	236 (45.3)	31.5 (5.2)	25.6 (4.8)	50	191 (18)	282 (8)	4.66 (0.29)	—	759 (100)
FinnGeDi-GDM	Finnish European	EPIC	266 (50.0)	32.5 (5.4)	27.8 (6.1)	56	165 (46)	278 (9)	5.27 (0.49)	—	982 (132)
Gen3G	European	EPIC	451 (47.5)	28.2 (4.3)	28.0 (5.5)	67	185 (7)	276 (7)	4.19 (0.38)	64 (73)	725 (129)
GUSTO	Chinese, Malay, Indian	450k	264 (49.4)	30.1 (5.4)	23.5 (5.1)	54	186 (19)	274 (7)	4.40 (0.49)	—	—
Healthy Start	Caucasian, Hispanic, African American	450k	532 (48)	27.6 (6.2)	26.0 (6.8)	42	125 (23)	277 (8)	4.27 (0.39)	92 (61)	867 (144)
PREDO	Finnish European	450k	552 (47.5)	33.5 (5.8)	28.8 (6.4)	67	185 (24)	280 (9)	4.89 (0.46)	—	822 (142)
ENVIRONAGE	European	EPIC	103 (45.6)	30.5 (4.5)	23.9 (4.1)	43	181 (24)	279 (9)	4.55 (0.71)	—	892 (146)
Generation R Study†	Dutch European	450k	1,101 (49)	31.5 (4.1)	24.0 (3.9)	39	92 (12)	282 (9)	4.33 (0.78)	141 (130)	—

Data are means (SD) unless otherwise indicated. Mat., maternal. †Nonfasting glucose and insulin data.

of Glucose regulation in Gestation and Growth [Gen3G] [15], U.S.: Healthy Start [16]), and Europe (Finland: the Finnish Gestational Diabetes [FinnGeDi] Study [7,17] and Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction [PREDO] study [18], France: EDEN [19], and Belgium: the ENVIRONAGE [20]). One cohort, in the Generation R Study (21) (the Netherlands), had nonfasting glycemic data (included in a secondary analysis). Apart from FinnGeDi (17), all studies included general population-based birth cohorts. Recruitment for the FinnGeDi control subjects (FinnGeDi-control) was similar to that for the other cohorts, while the FinnGeDi case subjects (FinnGeDi-GDM) were recruited and glycemic markers were measured much earlier in pregnancy (12–16 weeks). Therefore, data for FinnGeDi-GDM and FinnGeDi-control were analyzed separately. Ethics approval and informed consent were obtained following national and international standards.

#### Meta-analysis: Participants and Exclusion Criteria

We provided the analysis plan with R scripts for running the EWAS to all interested cohorts (Supplementary Material). Investigators for cohorts measured DNAm in cord blood using either the Illumina Infinium HumanMethylation450 (450k) or Illumina MethylationEPIC (EPIC) BeadChip array, which was normalized as investigators deemed appropriate (Supplementary Material, including Supplementary Table 1). Only term singletons (gestational age [GA] >37 weeks) were included in the analyses. We excluded siblings and offspring from mothers with type 1 or type 2 diabetes prior to the pregnancy.

#### Glycemia-Related Traits (Exposure)

We investigated three glycemia-related traits as continuous exposures: fasting glucose (FG) (in millimoles per liter), fasting insulin (FI) (in picomoles per liter, log<sub>2</sub> transformed), and AUC<sub>gluc</sub> (mmol/L\*min). For each cohort, maternal blood samples were collected by trained professionals. If multiple measurements were available during pregnancy, the earliest measurement was used. If samples were collected during an OGTT, the glucose and/or insulin concentration at the start of the OGTT was used as the “fasting” measure. The

Generation R Study had standardized, but nonfasting, glucose and insulin measurements available ( $N \approx 1,100$ ) (6). The OGTT were performed with a bolus of 50 g (ENVIRONAGE), 75 g (FinnGeDi, PREDO, and Gen3G), or 100 g pure glucose (EDEN, Healthy Start) in accordance with respective national guidelines. The  $AUC_{gluc}$  was calculated from glucose concentrations (in millimoles per liter) measured at time 0, 60, and 120 min with the method of Matthew et al. *BMJ* 1990, appendix II.

### Cohort-Specific Analyses

For all analyses, DNAm was analyzed as normalized untransformed  $\beta$  values.  $\beta$  values denote DNAm levels, where 0 approximates 0% and 1 approximates 100%. Effect estimates were converted to percentages throughout the manuscript with multiplication of the  $\beta$  values by 100. Investigators for each cohort performed EWAS on glucose/insulin/ $AUC_{gluc}$  using robust linear regression (rlm) from the R MASS package with the White estimator for robust SEs, as implemented in the R package sandwich (22), which leads to a model robust for outlying  $\beta$  values and heteroscedasticity. We used the  $\beta$  values of each CpG as the outcome and each of the glycemic variables as the predictor in separate models. Directed acyclic graphs (Supplementary Material) were used to investigate and determine the necessary minimal set of covariates to include in the model. Each EWAS was adjusted for the sex of the child (female/male), GA at maternal glycemic samplings (days), maternal age (years), GA at birth (days), parity (nulliparous yes/no), and imputed cord blood cell proportions (23) from the estimateCellCounts function in the minfi R package (24) with use of the “Bakulski reference” data set for cord blood. In addition, investigators of the cohorts were instructed to adjust for cohort-specific variables as needed (Supplementary Material). EWAS results from each cohort were evaluated with the R QCEWAS package (25).

### Meta-analysis

After quality control, we filtered out all probes that 1) did not map to unique genomic locations, 2) overlapped single nucleotide polymorphisms (minor allele frequency  $>5\%$  in 1,000 genomes), or 3) had  $>0.2$  mean  $\beta$  value differences

between the 450k and EPIC array (26). EWAS often suffer from deflation/inflation ( $\lambda$ ) and bias ( $\mu$ ) (as apparent in quantile-quantile plots [QQ-plots]) in the test statistic distribution, which may lead to spurious findings (27). We therefore used the R Bioconductor package bacon to estimate and mitigate the  $\lambda$  and  $\mu$  for each EWAS (27) (Supplementary Tables 2, 3, and 4). A fixed-effects meta-analysis with inverse variance weighting was then run for the cohort-specific bacon adjusted results for FG, FI, and  $AUC_{gluc}$  with the R package metafor (28). We also ran leave-one-out analyses for all probes using metafor. Heterogeneity was assessed with the Cochran  $Q$  test. In the meta-analysis with FG as an exposure, we observed genome-wide heterogeneity (Supplementary Fig. 1A), and the EDEN cohort was identified as the source of heterogeneity (Supplementary Fig. 1B), so in the final FG meta-analysis we excluded EDEN ( $N = 2,404$ ). The addition of nonfasting data from the Generation R Study did not introduce heterogeneity (Supplementary Figs. 2 and 3). Among the six cohorts for which values were provided for  $AUC_{gluc}$ , in EDEN ( $N = 32$ ), ENVIRONAGE ( $N = 86$ ), and Healthy Start ( $N = 48$ ) only measurements of women at high risk of developing GDM were included. There was heterogeneity in the meta-analysis (Supplementary Fig. 4A), which was mitigated with omission of these three cohorts (Supplementary Fig. 4B–D). The removal of the FinnGeDi-GDM sample had no effect on heterogeneity (Supplementary Fig. 4E). Therefore, in this meta-analysis we excluded EDEN, ENVIRONAGE, and Healthy Start but included the FinnGeDi-GDM sample. The meta-analyses were performed by two independent analysts to reduce the possibility of human error. All reported  $P$  values are two sided, and multiple testing corrections were performed with use of Benjamini-Hochberg (i.e., false discovery rate [FDR]).  $P$  values corrected by FDR are designated as  $P_{FDR}$ .  $P$  values that were not corrected by FDR (for instance, from lookup analyses) are designated as  $P_{nominal}$ . In EWAS meta-analyses, raw  $P_{nominal}$  values  $<1 \times 10^{-6}$  were deemed suggestive and  $P_{FDR}$  values  $<0.05$  were considered statistically significant. All probes were annotated to the human reference genome version 19, build 37. Meta-analysis results are deposited to

the EWAS catalog (29), Zenodo DOI <https://doi.org/10.5281/zenodo.5886997>. The presence of differentially methylated regions (DMR) in relation to the glycemic exposures was evaluated with the R packages ipDMR (30) and DMRcate (31), with use of each respective meta-analysis test statistic file. A DMR was considered robust if identified with both methods.

### Cross-sectional Lookup Analyses

For the Study in TEENs of the natural course of type 1 DIABetes (TEENDIAB) cohort (11) (Germany) and the Northern Finland birth cohort of 1966 (NFBC 1966) (12), DNAm data were provided for blood of children and adults, respectively, for conducting cross-sectional lookup analyses for loci of interest with cardiometabolic phenotypes. In addition, investigators for the Biological Atlas of Severe Obesity (ABOS) study (France) (13) provided DNAm and RNA-sequencing data for liver and muscle tissue from adult women with obesity who had undergone gastric bypass surgery (Supplementary Material). In all three cohorts, we used rlm to determine the association between DNAm at specific probes and each phenotype of interest. In the TEENDIAB cohort analyses, we adjusted for the child's sex, the age of the child (years), maternal type 1 diabetes status (binary), six imputed blood cell types (32), parental socioeconomic status (low, medium, and high), and batch (sentrix position). In the NFBC1966 (adults), we adjusted for sex, the imputed blood cell types (32), socioeconomic status (low, medium, or high), and batch. For the ABOS cohort, we adjusted for age (years), BMI, and type 2 diabetes status (binary).

## RESULTS

### Cohort Summaries

Characteristics of each cohort are described in Table 1. Mean maternal age ranged from 27.6 to 33.5 years and mean BMI from 23.9 to 28.8  $kg/m^2$ . The French EDEN cohort had the lowest mean FG (4.3 mmol/L), while the Finnish cohorts had the highest mean FG (FinnGeDi-control 4.6 mmol/L, FinnGeDi-GDM 5.3 mmol/L, PREDO 4.9 mmol/L). Mean FI differed between Gen3G (64 pmol/L) and Healthy Start (92 pmol/L), likely due to a lack of standardization of this measurement.

### Glucose and Insulin

The maternal FG meta-analysis ( $N = 2,404$ ,  $\lambda = 1.047$ ,  $\mu = 0.056$ ) yielded evidence for an association between FG and DNAm at CpG cg26104143 ( $\beta$  [SE]  $-0.26$  [0.04],  $P_{FDR} = 6.6 \times 10^{-3}$ ,  $N = 2,404$ ) (Table 2). This CpG (chromosome [chr]4: 41874579–41874580) is located upstream of *TMEM33*. The heterogeneity for association at this specific CpG was considerable ( $I^2 = 42\%$ ) and driven by the ENVIRONAGE cohort (Supplementary Fig. 5), as the association was attenuated and no longer significant after exclusion of ENVIRONAGE ( $\beta$  [SE]  $-0.09$  [0.07],  $P_{nominal} = 0.19$ ). Adding nonfasting glucose data from the Generation R Study did not reveal CpGs reaching statistical significance ( $P_{FDR} > 0.073$ ,  $N = 3,503$ ,  $\lambda = 1.042$ ,  $\mu = 0.059$ ) (Table 2). No robust DMRs were identified for FG.

Next, we investigated FI, which was measured in Gen3G ( $N = 438$ ) and Healthy Start ( $N = 523$ ). We did not find evidence of a statistically significant association between maternal FI and DNAm in offspring cord blood ( $P_{FDR} > 0.11$ ,  $N = 961$ ,  $\lambda = 1.027$ ,  $\mu = -0.078$ ). Adding nonfasting insulin data from the Generation R Study did not reveal CpGs reaching statistical significance ( $P_{FDR} > 0.14$ ,  $N = 2,062$ ,  $\lambda = 1.036$ ,  $\mu = 0.004$ ). The CpGs at which DNAm was nominally associated with FI or FG ( $P_{nominal} < 1 \times 10^{-6}$ ) are

presented in Table 2. No robust DMRs were identified for FI.

### Glycemic Excursion During the OGTT

The  $AUC_{gluc}$  meta-analysis that included data from FinnGeDi, Gen3G, and PREDO ( $N = 1,505$ ,  $\lambda = 1.027$ ,  $\mu = -0.004$ ) identified significant associations between a higher  $AUC_{gluc}$  and lower DNAm at cg26974062 ( $\beta$  [SE]  $-0.013$  [ $2.1 \times 10^{-3}$ ],  $P_{FDR} = 5.1 \times 10^{-3}$ ,  $N = 953$ ) and cg02988288 ( $\beta$  [SE]  $-0.013$  [ $2.3 \times 10^{-3}$ ],  $P_{FDR} = 0.031$ ,  $N = 953$ ). These two CpGs are located in thioredoxin interacting protein (*TXNIP*) (cg26974062 at chr1, 145440734, and cg02988288 at chr1, 145440445) (Fig. 1A). The meta-analysis on FG identified suggestive associations with lower DNAm at both *TXNIP* CpGs (Table 2) (cg26974062,  $\beta$  [SE]  $-3.0$  [0.56],  $P_{nominal} = 3.0 \times 10^{-7}$ ,  $N = 1,056$ ; cg02988288,  $-3.2$  [0.64],  $P_{nominal} = 1.8 \times 10^{-6}$ ,  $N = 1,056$ ), consistent with the direction of effect observed in our EWAS for  $AUC_{gluc}$ .

DNAm at the probes located upstream (+5 kb) of these CpGs were not associated with  $AUC_{gluc}$  ( $P_{nominal} > 0.29$ ). Directly downstream of the newly identified CpGs, DNAm at cg19693031 (chromosome 1: 145441552) has been associated previously with multiple adult metabolic traits and the risk of type 2 diabetes development (33). In our data set, cord blood DNAm at

cg19693031 was nominally associated with a greater  $AUC_{gluc}$  ( $\beta$  [SE]  $-1.0 \times 10^{-5}$  [ $4.4 \times 10^{-6}$ ],  $P_{nominal} = 0.019$ ,  $N = 1,505$ ) and with higher maternal FG ( $-0.4$  [0.1],  $P_{nominal} = 9.4 \times 10^{-6}$ ,  $N = 2,404$ ) but not with FI ( $P_{nominal} = 0.60$ ) (Fig. 1A). However, this region was not designated as a DMR and we did not identify any robust DMRs for  $AUC_{gluc}$ .


Despite mitigation of genome-wide heterogeneity, heterogeneity was high for associations between  $AUC_{gluc}$  and cord blood DNAm at cg26974062 ( $I^2 = 52.1\%$ ) and cg02988288 ( $I^2 = 60.3\%$ ). Both CpGs are represented on the EPIC array but not the 450k array (unlike cg19693031, which is present on both). Therefore, both probes were only available for the two FinnGeDi groups and Gen3G. The heterogeneity for these probes originated from a lack of association among offspring born to FinnGeDi-GDM mothers (Supplementary Fig. 6). A similar observation was made in stratification of Gen3G participants by GDM status (Fig. 1B). However, there was no statistical evidence of interaction to support a moderating effect of GDM in either the FinnGeDi or Gen3G cohorts ( $P_{AUC_{gluc} \times GDM} > 0.10$ ). Excluding GDM pregnancies from the  $AUC_{gluc}$  meta-analysis did not reveal any additional CpGs, apart from cg26974062 and cg02988288, reaching statistical significance thresholds (data not shown).

**Table 2—Cord blood DNAm associations with maternal glycemic traits ( $P$  value  $< 1.0 \times 10^{-6}$ )**

Glycemic trait	Probe identifier	Position (hg19)	Nearest gene	Restricting to fasting participants				Including nonfasting participants			
				$N$	$\beta$ (SE)	$P^\dagger$	$I^2$	$N$	$\beta$ (SE)	$P^\dagger$	$I^2$
Glucose	cg26104143	chr4: 41869579	<i>TMEM33</i>	2,404	$-0.26$ (0.04)	$7.9 \times 10^{-9}$	42.7	3,503	$-0.18$ (0.033)	$1.1 \times 10^{-7}$	62.2
Glucose	cg26974062	chr1: 145440734	<i>TXNIP</i>	1,056	$-3.0$ (0.56)	$3.0 \times 10^{-7}$	0	1,056	$-3.0$ (0.56)	$2.6 \times 10^{-7}$	0
Glucose	cg21686486	chr2: 172377802	<i>CYBRD1</i>	1,056	1.2 (0.22)	$3.2 \times 10^{-7}$	57.4	1,056	1.2 (0.22)	$2.8 \times 10^{-7}$	57.4
Insulin	cg21139325	chr6: 32729470	<i>HLA-DQB2</i>	961	0.55 (0.11)	$2.8 \times 10^{-7}$	0	2,062	0.16 (0.029)	$3.1 \times 10^{-7}$	15.2
$AUC_{gluc}$	cg26974062	chr1: 145440734	<i>TXNIP</i>	953	$-0.013$ ( $2.1 \times 10^{-3}$ )	$6.3 \times 10^{-9}$	52.1				
$AUC_{gluc}$	cg02988288	chr1: 145440445	<i>TXNIP</i>	953	$-0.013$ ( $2.3 \times 10^{-3}$ )	$7.9 \times 10^{-8}$	60.4				
$AUC_{gluc}$	cg09049566	chr5: 132165605	<i>SHROOM1</i>	1,505	$-2.0 \times 10^{-3}$ ( $3.9 \times 10^{-4}$ )	$9.2 \times 10^{-7}$	1.9				

Overview of the meta-analysis results with a  $P$  value  $< 1.0 \times 10^{-6}$  after correction for inflation/bias with the bacon R package. The used rlm with robust SEs was as follows:  $\beta$  value ~ glycemic trait + GA at maternal sampling + sex of the child + imputed cord blood cell proportions + maternal age + GA at birth + parity and cohort-specific (technical) variables.  $^\dagger P$  value after correction for inflation and bias with the bacon R package. Correction is based on the entire distribution of test statistics of each meta-analysis and may therefore (slightly) differ between the fasted and combined meta-analyses as the sample size is increased for many CpGs.





**Figure 1**—Overview of findings at *TXNIP*. **A**: Chromosomal and gene map for the *TXNIP* locus (top), followed with the locations of the CpGs incorporated in the meta-analysis. Highlighted with red dotted lines are CpGs cg02988288, cg26974062, and cg19693031 in the panels with  $-\log_{10}$  nominal *P* values for the meta-analyses on FG, FI, and AUC<sub>gluc</sub> for the measured CpGs in *TXNIP*. **B**: Forest plot for the AUC of an OGTT meta-analysis stratified by GDM status for the two CpGs that were genome-wide significant. Gen3G-GDM, GDM case subjects from the Gen3G cohort; NCBI, National Center for Biotechnology Information; FE, fixed-effect.

**Cross-sectional Lookups**

To investigate whether DNAm at the two newly identified CpG sites in *TXNIP*

may play a role in offspring metabolic health, we investigated associations between blood DNAm at these two

CpGs and metabolic phenotypes at various time points across the life span. First, we did an in silico lookup analysis

using data from TEENDIAB (11), a prospective study where DNAm (EPIC array) was measured in the blood of children (4–19 years of age) born to mothers with ( $N = 162$ ) or without ( $N = 221$ ) type 1 diabetes, a condition characterized by relative maternal hyperglycemia during pregnancy in the majority of women, despite tight glycemic targets. Exposure to maternal type 1 diabetes in utero was associated with lower child blood DNAm at both cg26974062 ( $\beta$  [SE]  $-0.76$  [0.34],  $P_{\text{nominal}} = 0.024$ ) and cg02988288 ( $-0.89$  [0.29],  $P_{\text{nominal}} = 2.4 \times 10^{-3}$ ), and the directions of effect were consistent with our analyses of AUC<sub>gluc</sub> and FG. In contrast, child blood DNAm at the four CpGs with suggestive associations with FG and FI (see Table 2) did not show associations with in utero exposure to maternal type 1 diabetes ( $P > 0.05$ ).

Next, we investigated cross-sectional associations between blood DNAm at these loci and metabolic phenotypes in childhood and adulthood. At both *TXNIP* CpGs, lower DNAm in childhood blood was associated with higher child HOMA of insulin resistance and, for cg02988288, higher FI (Table 3 and Supplementary Table 5). Similarly, using metabolic traits in adults at 46 years of age in NFBC1966, we observed consistent negative cross-sectional associations between blood DNAm at cg26974062 and cg02988288 and all of the metabolic traits tested (serum glucose, insulin, AUC<sub>gluc</sub>, HbA<sub>1c</sub>, and BMI) (Table 3 and

Supplementary Table 4). In contrast, of the CpGs that showed suggestive associations with FG and FI in our meta-analysis (Table 2), we only found cg21139325 to be nominally associated with adult BMI (Supplementary Table 6).

Finally, we investigated DNAm levels at cg26974062 and cg02988288 and *TXNIP* expression measured in muscle and liver biopsies of women with obesity in the ABOS cohort (13). Lower DNAm at cg26974062 ( $\beta$  [SE]  $-1.1 \times 10^{-2}$  [ $5.2 \times 10^{-3}$ ],  $P_{\text{nominal}} = 0.031$ ,  $N = 319$ ) and cg02988288 ( $-4.5 \times 10^{-2}$  [ $1.2 \times 10^{-2}$ ],  $P_{\text{nominal}} = 3.2 \times 10^{-4}$ ,  $N = 319$ ) was associated with higher *TXNIP* gene expression in liver but not in muscle ( $N = 71$ ). In contrast, the CpGs with suggestive associations with FG and FI (Table 2) were not associated with gene expression (Supplementary Table 7).

#### Lookups in Literature

We checked the CpGs that we identified (Table 2) in the EWAS catalog (29), which documents (suggestive) associations ( $P < 10^{-4}$ ). Cord blood DNAm at cg26974062 had a nominal association with maternal 1-h glucose in the UK Pregnancies Better Eating and Activity Trial (UPBEAT) (5). Next, we checked recently published data on maternal HbA<sub>1c</sub> levels and cord blood DNAm (Gen3G [ $N = 412$ ]) (8), and both *TXNIP* probes showed nominal associations with maternal HbA<sub>1c</sub> (cg02988288,  $\beta$  [SE]  $-4.5$  [0.16],  $P_{\text{nominal}} = 3.9 \times 10^{-3}$ ;

cg26974062,  $-3.8$  [1.5],  $P_{\text{nominal}} = 0.012$ ) in a direction consistent with that of our AUC<sub>gluc</sub> and FG meta-analyses. None of the other CpGs with suggestive associations in Table 2 were associated with maternal HbA<sub>1c</sub>. Finally, the CpGs that showed (suggestive) associations with FG, FI, and AUC<sub>gluc</sub> were not associated with GDM (or probes were not available) in the prior PACE meta-analysis ( $P_{\text{nominal}} > 0.48$ ) (9).

In “reverse lookups,” we found little evidence for the reported associations with maternal FG and 1-h or 2-h glucose from UPBEAT participants cord blood analyses: only 5 of 609 reported CpGs for 1-h or 2-h glucose were nominally associated with AUC<sub>gluc</sub> with the same direction of effect (namely, cg24914185, cg13874780, cg04322572, cg03795071, and cg23913963) (5). Cord blood DNAm at a CpG near *URGCP* reportedly associated with maternal HbA<sub>1c</sub> (8) was not associated with any glycemic trait in our meta-analyses ( $P_{\text{nominal}} > 0.074$ ), and none of the CpGs located in DMRs identified for GDM in a prior PACE report were associated either (9) ( $P_{\text{nominal}} > 0.18$ ).

#### CONCLUSIONS

We did not find evidence for robust associations between maternal prenatal glucose and insulin levels and offspring DNAm in cord blood (9). Collectively, these findings might argue against the

**Table 3—Cross-sectional associations of blood DNAm at cg02988288 and metabolic phenotypes in childhood and adulthood**

	TEENDIAB participants (German Europeans ages 4–19 years [49.6% female])§			NFBC1966 participants (Finnish Europeans ages 46 years [56% female])†		
	$\beta$ (SE)	<i>P</i>	<i>N</i>	$\beta$ (SE)	<i>P</i>	<i>N</i>
Fasting plasma glucose (mmol/L)	−0.37 (0.30)	0.22	366	−0.71 (0.16)	$1.20 \times 10^{-5}$	680
Fasting plasma insulin (pmol/L)	−0.41 (0.17)	0.014	369	−0.044 (0.013)	$9.9 \times 10^{-4}$	685
AUC <sub>gluc</sub> (mmol/L*min)	$-1.4 \times 10^{-3}$ ( $1.5 \times 10^{-3}$ )	0.33	232	$-2.1 \times 10^{-3}$ ( $6.5 \times 10^{-4}$ )	$1.3 \times 10^{-3}$	589
BMI (kg/m <sup>2</sup> )	$-7.3 \times 10^{-2}$ ( $5.3 \times 10^{-2}$ )	0.17	383	−0.077 (0.022)	$5.0 \times 10^{-4}$	693
Body fat (bio-impedance)	NA	NA	NA	−0.039 (0.014)	$4.3 \times 10^{-3}$	671
Waist-to-hip ratio	−0.14 (0.17)	0.42	365	NA	NA	NA
HOMA-IR	−0.29 ( $8.4 \times 10^{-2}$ )	$5.0 \times 10^{-4}$	365	NA	NA	NA
HbA <sub>1c</sub> (mmol/L)	$-8.5 \times 10^{-3}$ ( $4.7 \times 10^{-2}$ )	0.85	361	−0.090 (0.024)	$2.6 \times 10^{-4}$	693
Type 2 diabetes	NA	NA	NA	−1.46 (0.52)	$4.7 \times 10^{-3}$	507

HOMA-IR, HOMA of insulin resistance. NA, not available for assessment. §Outcome of analyses in the TEENDIAB cohort. Columns denote the results from an rlm with robust SEs adjusting for sex, age at blood draw, batch, imputed cell heterogeneity, maternal type 1 diabetes status, and parental socioeconomic status. †Outcome of analyses in NFBC1966. The results from an rlm with robust SEs adjusting for sex, batch, imputed cell proportions, and socioeconomic status.

hypothesis that maternal hyperglycemia during pregnancy and later childhood health phenotypes can be mediated by changes in DNAm (4). However, our meta-analysis of  $AUC_{gluc}$  did reveal inverse associations with cord blood DNAm at two CpG sites located within an exon of *TXNIP* (cg26974062 and cg02988288). In analyses stratified by GDM status, these associations were only observed among participants without GDM. Consistent with an interpretation that this association reflects an association with maternal hyperglycemia, we found that exposure to higher maternal FG,  $HbA_{1c}$  and maternal type 1 diabetes was also nominally associated with a lower DNAm in *TXNIP* in (cord) blood. In addition, we found suggestive associations with liver gene expression and multiple metabolic traits.

*TXNIP* encodes for a thioredoxin-interacting protein involved in the regulation of glucose-sensing and redox processes. Several studies meta-analyzed by Walaszczyk et al. (33) have reported associations between blood DNAm at cg19693031 (also located in *TXNIP*) and lipid traits, type 2 diabetes, and prediabetes. Upon lookup in the results of our present meta-analysis, we observed evidence for associations between maternal  $AUC_{gluc}$  and FG and cord blood DNAm levels for cg19693031, which is located downstream of cg26974062 and cg02988288. Furthermore, we found that the methylation at *TXNIP* was negatively associated with *TXNIP* gene expression in the liver, but not in skeletal muscle, further supporting the role of liver *TXNIP* as a future therapeutic target. In fact, a *TXNIP* inhibitor (SRI-37330) is currently under investigation as a therapeutic target for diabetes (34). We found both cg26974062 and cg02988288 to be associated with multiple cardiometabolic traits. To date, only one other study has reported an association for both probes, namely, with type 2 diabetes (35). Both probes are unique to the EPIC array; it is therefore possible that these associations were missed in previous studies, which have largely used the 450k array.

Interestingly, we observed a high level of heterogeneity for the associations between DNAm at cg26974062 and cg02988288 and maternal  $AUC_{gluc}$  potentially due to a lack of association among participants with GDM. In included studies, the women with GDM were instructed to

self-monitor their blood glucose, modify their diet and physical activity, and, if necessary, use pharmacologic agents aiming to normalize their blood glucose levels. Adequate glucose control can prevent GDM-associated pregnancy complications, but the effect of GDM treatment on long-term offspring health remains an unresolved question (36). We speculate that by moderating maternal hyperglycemia during the last trimester of pregnancy, GDM treatment may also influence the association between maternal  $AUC_{gluc}$  and cord blood DNAm at *TXNIP*. Consistent with this hypothesis, it was reported that the associations between maternal glycemia during pregnancy and cord blood DNAm were attenuated as a result of UPBEAT where mothers were randomized to a lifestyle intervention during pregnancy (5). In this latter study, lower cord blood DNAm at cg26974062 was nominally associated with higher maternal 1-h glucose (with a direction of effect consistent with our  $AUC_{gluc}$  meta-analysis) and cord blood DNAm at cg02988288 was associated with GDM; however, the association between GDM and cord blood DNAm at cg02988288 did not seem attenuated by the UPBEAT lifestyle intervention.

Our study has several limitations. First, while this collaborative effort is, to our knowledge, the largest inquiry on this topic to date, our sample size remains modest and may have been underpowered to detect some smaller associations against the null hypothesis (37). Second, our meta-analysis covered a small fraction of the known 28 million CpGs of the human epigenome. This limitation is somewhat remedied by the EPIC array, as it covers most known enhancers (26), which may be particularly sensitive to prenatal exposures (38). However, this array was used for only half of the cohorts. Another known limitation (37) is that we measured DNAm in (cord)blood and our results may be influenced by tissue heterogeneity and may not extrapolate to other tissues. Similarly, genetic variation may likewise influence DNAm. With the exception of cg21139325 (*HLA-DQB2*) (39), no genetic variation was reported to be associated with blood DNAm among the identified CpGs (in Table 2). Another important consideration is that nutritional status and maternal glucose levels as early as gestational weeks 4–12 have been associated

with postnatal growth (40), and studies of prenatal famine exposure have indicated that early gestation is an especially sensitive window for remethylation, which happens during this period (37). We are unable to test the influence of gestational timing of maternal glycemic exposures. However, in a recent study with comparison of the association between early and late measures of maternal  $HbA_{1c}$  during pregnancy and cord blood DNAm, no evidence was found for robust associations related to early pregnancy exposure (8).

In conclusion, our meta-analyses of maternal glycemic traits identified one sole exon of *TXNIP* at which higher maternal hyperglycemia, as reflected by higher  $AUC_{gluc}$  (and to a lesser extent FG, type 1 diabetes, and  $HbA_{1c}$ ), was robustly associated with lower cord blood DNAm, and we found that these associations were attenuated in treated GDM pregnancies. We found little evidence for additional associations between maternal glucose and insulin levels during midpregnancy/late pregnancy and the cord blood methylome. In suggestive lookup analyses, *TXNIP* blood DNAm in childhood was similarly associated with prenatal exposure to maternal type 1 diabetes. *TXNIP* blood DNAm later in life was cross-sectionally associated with glycemic and anthropometric variables. Thus, future investigations of the links of in utero hyperglycemia exposure, DNAm at *TXNIP*, and cardiometabolic health across the life course are warranted.

**Acknowledgments.** The authors thank the participants of the precision nutri-Epigenetic approach to tackle the PRECISION nutri-Epigenetic approach to tackle the mother-to-child transmission of impaired glucose metabolism (PREcisE) project for interesting discussion and feedback.

**Duality of Interest.** N.K. and Y.S.C. are part of an academic consortium that has received research funding from Abbott Nutrition, Nestec, and Danone. Y.S.C. has received reimbursement for speaking at conferences sponsored by companies selling nutritional products. No other potential conflicts of interest relevant to this article were reported.

These parties did not have any role in this research, the content of the manuscript, or the decision to publish.

**Funding.** E.W.T. was supported by a VENI grant from the Netherlands Organization for Scientific Research (91617128). This work was funded by the Joint Programming Initiative – A Healthy Diet for a Healthy Life (JPI HDHL) (proposal number 655). In the U.K. it is jointly funded by the Medical Research Council and the Biotechnology and



Biological Sciences Research Council (grant MR/S03658X/1), in Spain by Instituto de Salud Carlos III (PCI2018-093147), in Germany by the German Federal Ministry of Education and Research (FKZ 01EA1905), in the Netherlands by ZonMw (529051023), and in France by French National Research Agency (ANR18-HDHL-0003-05). J.R. and S.S. received funding from the Healthy Diet for a Healthy Life (JPI HDHL) (PREcisE proposal no. 655) and the European Union's Horizon 2020 research and innovation program under grant agreement nos. 733206 (LifeCycle), 824989 (EUCAN-Connect), 874739 (Longitools), and 848158 (EarlyCause). Information regarding funding for the contributing cohorts can be found in Supplementary Material.

**Author Contributions.** The contributor roles taxonomy (CRediT) was as follows: E.W.T., C.G.H., M.-F.H., and S.S. contributed to study conceptualization. E.W.T. developed study methodology. E.W.T., D.L.J.-Q., J.R., and R.O. undertook the investigation. E.W.T., D.L.J.-Q., J.R., R.O., R.A., M.L.G., L.K.K., I.Y.L., G.P., J.T., A.P.S., and S.H. contributed to formal analysis. E.W.T. and D.L.J.-Q. performed the validation. I.Y.L., E.B., R.C., R.G., P.D.G., E.Ke., N.K., S.M., T.S.N., F.P., M.P., V.R., K.H.T., C.W., A.G.Z., I.A.-M., Y.S.C., D.D., J.F.F., B.H., V.W.V.J., J.L., M.V., A.B., P.F., S.H., E.Ka., M.-R.J., M.-F.H., M.C., A.K., J.K.Y.C., B.R., and S.S. provided (cohort) resources. E.W.T. and D.L.J.-Q. contributed to meta-analysis data curation. E.W.T. and S.S. contributed to writing the original draft of the manuscript. All authors contributed to review and editing of the manuscript. E.W.T. undertook the visualization. M.-R.J., C.G.H., M.-F.H., and S.S. contributed to study supervision. E.W.T., E.T., M.-R.J., C.G.H., M.-F.H., R.P.M.S.-T., and S.S. contributed to project administration. E.W.T., P.P., R.G., P.D.G., N.K., T.S.N., K.R., A.G.Z., I.A.-M., L.B., Y.S.C., D.D., J.F.F., B.H., V.W.V.J., J.L., M.V., S.H., E.Ka., M.-R.J., M.-F.H., R.P.M.S.-T. and S.S. contributed to funding acquisition. E.W.T. and S.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

## References

- Metzger BE, Lowe LP, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991–2002
- Metzger BE, Lowe LP, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. *Diabetes* 2009;58:453–459
- Väärasmäki M, Pouta A, Elliot P, et al. Adolescent manifestations of metabolic syndrome among children born to women with gestational diabetes in a general-population birth cohort. *Am J Epidemiol* 2009;169:1209–1215
- Hjort L, Novakovic B, Grunnet LG, et al. Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child's epigenome and later risk of disease. *Lancet Diabetes Endocrinol* 2019;7:796–806
- Antoun E, Kitaba NT, Titcombe P, et al.; UPBEAT Consortium. Maternal dysglycaemia, changes in the infant's epigenome modified with a diet and physical activity intervention in pregnancy: secondary analysis of a randomised control trial. *PLoS Med* 2020;17:e1003229
- Geurtsen ML, Jaddoe VVW, Gaillard R, Felix JF. Associations of maternal early-pregnancy blood glucose and insulin concentrations with DNA methylation in newborns. *Clin Epigenetics* 2020;12:134
- Canouiil M, Khamis A, Keikkala E, et al. Epigenome-wide association study reveals methylation loci associated with offspring gestational diabetes mellitus exposure and maternal methylome. *Diabetes Care* 2021;44:1992–1999
- Juviniao-Quintero DL, Starling AP, Cardenas A, et al. Epigenome-wide association study of maternal hemoglobin A1c in pregnancy and cord blood DNA methylation. *Epigenomics* 2021;13:203–218
- Howe CG, Cox B, Fore R, et al. Maternal gestational diabetes mellitus and newborn DNA methylation: findings from the Pregnancy and Childhood Epigenetics consortium. *Diabetes Care* 2020;43:98–105
- Zhang C, Wei Y, Sun W, Yang H. The area under the curve (AUC) of oral glucose tolerance test (OGTT) could be a measure method of hyperglycemia in all pregnant women. *Open J Obstet Gynecol* 2019;09:186–195
- Ziegler AG, Meier-Stiegen F, Winkler C; TEENDIAB Study Group. Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty—TEENDIAB: study design. *Pediatr Diabetes* 2012;13:419–424
- Rantakallio P. The longitudinal study of the Northern Finland birth cohort of 1966. *Paediatr Perinat Epidemiol* 1988;2:59–88
- Margerie D, Lefebvre P, Raverdy V, et al. Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. *BMC Med Genomics* 2019;12:80
- Soh S-E, Tint MT, Gluckman PD, et al.; GUSTO Study Group. Cohort profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. *Int J Epidemiol* 2014;43:1401–1409
- Guillemette L, Allard C, Lacroix M, et al. Genetics of Glucose regulation in Gestation and Growth (Gen3G): a prospective prebirth cohort of mother-child pairs in Sherbrooke, Canada. *BMJ Open* 2016;6:e010031
- Starling AP, Liu C, Shen G, et al. Prenatal exposure to per- and polyfluoroalkyl substances, umbilical cord blood DNA methylation, and cardio-metabolic indicators in newborns: the Healthy Start study. *Environ Health Perspect* 2020;128:127014
- Keikkala E, Mustaniemi S, Koivunen S, et al. Cohort profile: the Finnish Gestational Diabetes (FinnGeDi) study. *Int J Epidemiol* 2020;49:762–763g
- Girchenko P, Lahti M, Tuovinen S, et al. Cohort profile: Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. *Int J Epidemiol* 2017;46:1380–1381g
- Heude B, Forhan A, Slama R, et al.; EDEN mother-child cohort study group. Cohort profile: the EDEN mother-child cohort on the prenatal and early postnatal determinants of child health and development. *Int J Epidemiol* 2016;45:353–363
- Janssen BG, Madhloum N, Gyselaers W, et al. Cohort profile: the ENVIRONMENTAL influence ON early AGEing (ENVIRONAGE): a birth cohort study. *Int J Epidemiol* 2017;46:1386–1387m
- Kooijman MN, Kruithof CJ, van Duijn CM, et al. The Generation R Study: design and cohort update 2017. *Eur J Epidemiol* 2016;31:1243–1264
- Zeileis A. Object-oriented computation of sandwich estimators. *J Stat Softw* 2006;16:1–16
- Salas LA, Koestler DC, Butler RA, et al. An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray. *Genome Biol* 2018;19:64
- Fortin JP, Triche TJ Jr, Hansen KD. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* 2017;33:558–560
- Van der Most PJ, Küpers LK, Snieder H, Nolte I. QCEWAS: automated quality control of results of epigenome-wide association studies. *Bioinformatics* 2017;33:1243–1245
- Pidsley R, Zotenko E, Peters TJ, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. *Genome Biol* 2016;17:208
- van Iterson M, van Zwet EW; BIOS Consortium. Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution. *Genome Biol* 2017;18:19
- Viechtbauer W. Conducting meta-analyses in R with the metafor. *J Stat Softw* 2010;36:1–48
- Batram T, Yousefi P, Crawford G, et al. The EWAS Catalog: a database of epigenome-wide association studies. 2 February 2021 [preprint]. OSF Preprints. Available from <https://osf.io/837wn/>
- Xu Z, Xie C, Taylor JA, Niu L. ipDMR: identification of differentially methylated regions with interval P-values. *Bioinformatics* 2021;37:711–713
- Peters TJ, Buckley MJ, Statham AL, et al. De novo identification of differentially methylated regions in the human genome. *Epigenetics Chromatin* 2015;8:6
- Reinius LE, Acevedo N, Joerink M, et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. *PLoS One* 2012;7:e41361
- Walaszczyk E, Luijten M, Spijkerman AMW, et al. DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA<sub>1c</sub> levels: a systematic review and replication in a case-control sample of the Lifelines study. *Diabetologia* 2018;61:354–368
- Thielen LA, Chen J, Jing G, et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucose glucagon action. *Cell Metab* 2020;32:353–365.e8
- Albao DS, Cutingco-de la Paz EM, Mercado ME, et al. Methylation changes in the peripheral blood of Filipinos with type 2 diabetes suggest spurious transcription initiation at TXNIP. *Hum Mol Genet* 2019;28:4208–4218
- Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and

- meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. *Ann Intern Med* 2013;159:123–129
37. Heijmans BT, Mill J. Commentary: the seven plagues of epigenetic epidemiology. *Int J Epidemiol* 2012;41:74–78
38. Tobi EW, Goeman JJ, Monajemi R, et al. DNA methylation signatures link prenatal famine exposure to growth and metabolism. *Nat Commun* 2014;5:5592
39. Min JL, Hemani G, Hannon E, et al.; BIOS Consortium. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet* 2021;53:1311–1321
40. Dong L, Liu E, Guo J, et al. Relationship between maternal fasting glucose levels at 4–12 gestational weeks and offspring growth and development in early infancy. *Diabetes Res Clin Pract* 2013;102:210–217